Immedica to commence tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc.
Stockholm, Sweden – January 8, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, today announced that it will commence a tender offer through its wholly owned, direct subsidiary Matador Subsidiary, Inc., a Delaware corporation (“Purchaser”), to purchase all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. (“Marinus”) (Nasdaq: MRNS) at a price of USD 0.55 per share in cash. The tender offer is being made pursuant to the Agreement and Plan of Merger announced on December 30, 2024, by and among Immedica, Marinus, and Purchaser. Immedica will